General University Hospital
Prague, 12800, Czechia
Location status: Recruiting
NCT Number: NCT06147388
The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.
Interested in participating?
Request Info18 year–40 year
Female
Observational
Prague, 12800, Czechia
Location status: Recruiting
Introduction There are three grades of dysplasia of the cervix based on their severity (CIN 1-3). Most women with CIN 2 or CIN 3 (high-grade - HG lesions) are referred for conization due to the presumed risk of developing invasive cervical cancer. However, this surgical intervention is associated with an increased risk of preterm labor in the future.
From the literature, it is evident that 30% - 60% of CIN 2 and CIN 3 lesions spontaneously regress. Colposcopic examination is a tool that can accurately assess the severity of the lesion and safely evaluate the dynamics of its development. It can be used to exclude the presence of invasive cervical cancer.
The aim of the study is to determine the absolute rate of spontaneous regression of HG lesions, considering stratification factors.
Methods Patients meeting all inclusion criteria and none of the exclusion criteria are included (see below). Colposcopic evaluations occur at four-month intervals during the study. In case of progression, the patient is indicated for conization; in case of persistence, the patient is consulted and can choose further observation or conization; in case of regression, punch biopsy is performed to acquire a histopathologic sample for primary endpoint evaluation. The biopsy/conization result is subsequently compared with the initial sample to declare regression or persistence of the HG lesion.
The HPV status and cytological findings are evaluated similarly. Stratification criteria such as age, colposcopic characteristics, HPV genotype (Cobas 4800, Roche Molecular Systems, Pleasanton, USA), methylation markers (GynTect®, Oncgnostics GmbH, Löbstedter Str. 41, 07749 Jena, Germany), semiquantitative microscopic assessment of the vaginal swab, and personal history are assessed during monitoring.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No surgery, observation
Time frame: 3 years
Histological results from the initial visit will be compared with the biopsy obtained during the last visit (or the specimen from conization) to determine whether regression or persistence of the high-grade lesion has occurred.
Time frame: 3 years
The proportion of patients with a negative result on the HPV DNA test obtained during the final visit will be assessed.
Time frame: 3 years
Time frame: 3 years
Specific factors will be evaluated to determine their influence on the regression or persistence of the cervical high-grade lesion. The following factors will be assessed:
Time frame: 3 years
Contact information is provided by the study sponsor or research team.
General University Hospital, Prague
Other
Acronym: RECER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05413798
CIN2, CIN3
Westdene, Johannesburg, South Africa
View Trial DetailsNCT04422366
AIS, CIN1
Liuzhou, Guangxi, China
View Trial DetailsNCT05371353
CIN1, CIN2
Yangchun, Guangdong, China
View Trial DetailsNCT05027776
CIN1, CIN2
Mianyang, Sichuan, China
View Trial Details